» Authors » Richard J Benjamin

Richard J Benjamin

Explore the profile of Richard J Benjamin including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 78
Citations 928
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Norris P, Stone M, Di Germanio C, Balasko B, Kaidarova Z, Friend H, et al.
Transfusion . 2025 Jan; PMID: 39801369
Background: Although alloimmunization risk of pathogen-reduced (PR) platelets has been studied, the risk has not been reported with PR red blood cells (RBCs). Study Design And Methods: In a Phase...
2.
Karim C, Panigrahi A, Pearl R, Sodha N, Beaver T, Pelletier J, et al.
Transfusion . 2024 Dec; 65(2):344-353. PMID: 39719927
Background: The clinical significance of natural and treatment-emergent antibodies specific for amustaline/glutathione pathogen-reduced red blood cells (PRRBCs) is not known. Study Design And Methods: A Phase 3, randomized clinical trial...
3.
North A, Ling K, Ricaud G, Stankowski Jr L, Daly J, Bentow S, et al.
Transfusion . 2024 May; 64(6):1097-1108. PMID: 38716879
Background: N-(-9 acridinyl)-b-alanine hydrochloride (S-300) is the main byproduct of red blood cell (RBC) amustaline/glutathione(GSH) pathogen reduction, currently undergoing phase III US clinical trials following successful European studies(1-3). Phosphatidylinositol glycan,...
4.
Wheeler A, Snyder E, Refaai M, Cohn C, Poisson J, Fontaine M, et al.
Blood Adv . 2024 Mar; 8(9):2290-2299. PMID: 38447116
Patients treated with antineoplastic therapy often develop thrombocytopenia requiring platelet transfusion, which has potential to exacerbate pulmonary injury. This study tested the hypothesis that amotosalen-UVA pathogen-reduced platelet components (PRPCs) do...
5.
Snyder E, Sekela M, Welsby I, Toyoda Y, Alsammak M, Sodha N, et al.
Trials . 2023 Dec; 24(1):799. PMID: 38082326
Background: Red blood cell (RBC) transfusion is a critical supportive therapy in cardiovascular surgery (CVS). Donor selection and testing have reduced the risk of transfusion-transmitted infections; however, risks remain from...
6.
Benjamin R
Blood . 2023 May; 141(21):2550-2551. PMID: 37227797
No abstract available.
7.
Pitman J, Payrat J, Park M, Liu K, Corash L, Benjamin R
Transfusion . 2023 Feb; 63(4):711-723. PMID: 36802055
Background: France converted to universal pathogen reduced (PR; amotosalen/UVA) platelets in 2017 and extended platelet component (PC) shelf-life from 5- to 7-days in 2018 and 2019. Annual national hemovigilance (HV)...
8.
Gammon R, Katz L, Strauss D, Rowe K, Menitove J, Benjamin R, et al.
Transfus Med . 2022 Aug; 33(1):6-15. PMID: 35918741
The COVID-19 pandemic severely tested the resilience of the US blood supply with wild fluctuations in blood donation and utilisation rates as community donation opportunities ebbed and hospitals post-poned elective...
9.
Cancelas J, Genthe J, Stolla M, Rugg N, Bailey S, Nestheide S, et al.
Transfusion . 2022 Jul; 62(8):1619-1629. PMID: 35808974
Background: Amotosalen/UVA pathogen-reduced platelet components (PRPCs) with storage up to 7 days are standard of care in France, Switzerland, and Austria. PRPCs provide effective hemostasis with reduced risk of transfusion-transmitted...
10.
Snyder E, Wheeler A, Refaai M, Cohn C, Poisson J, Fontaine M, et al.
Transfusion . 2022 Jun; 62(7):1365-1376. PMID: 35748490
Background: Platelet transfusion carries risk of transfusion-transmitted infection (TTI). Pathogen reduction of platelet components (PRPC) is designed to reduce TTI. Pulmonary adverse events (AEs), including transfusion-related acute lung injury and...